Skip to content

Lung adenocarcinoma — EGFR disease

TL;DR — EGFR-mutant adenocarcinoma is the foundational biomarker-defined lung cancer. IPASS showed that gefitinib improved PFS only in mutation-positive tumors (HR 0.48) and harmed the mutation-negative subgroup relative to chemotherapy (HR 2.85), establishing genotype—not demographic phenotype—as the treatment selector (Mok 2009, PMID 19692680). Osimertinib became the metastatic first-line backbone through FLAURA, improving PFS and overall survival with strong CNS activity (Soria 2018, PMID 29151359; Ramalingam 2020, PMID 31751012). New first-line intensification with platinum-pemetrexed or amivantamab-lazertinib prolongs PFS but adds toxicity, leaving selection unresolved (Planchard 2023, PMID 37937763; Cho 2024, PMID 38924756). In resected stage IB–IIIA disease, three years of adjuvant osimertinib improved DFS and OS, but duration, retreatment, and cure fraction remain active questions (Wu 2020, PMID 32955177; Tsuboi 2023, PMID 37272535).

The biomarker-defined disease

EGFR class Examples Sensitivity frame
Classical sensitizing Exon 19 deletion, L858R Osimertinib-based first line
Uncommon sensitizing G719X, L861Q, S768I Variable; afatinib/osimertinib evidence mostly non-randomized
Exon 20 insertion Diverse in-frame insertions Resistant to conventional-dose first/third-generation TKIs; amivantamab-based strategy
Primary resistant Many exon 20 insertions, rare kinase-domain variants Variant-specific interpretation needed
Acquired resistance T790M after early TKIs; C797S after osimertinib Treatment-history and allelic context matter

EGFR prevalence is population-dependent. PIONEER found mutations in 51.4% of 1,450 evaluable advanced Asian adenocarcinomas, with country, sex, ethnicity, and smoking effects (Shi 2014, PMID 24419411). Never-smoking phenotype enriches probability but cannot replace testing.

IPASS and the predictive-biomarker lesson

IPASS randomized clinically selected East Asian never/light smokers with pulmonary adenocarcinoma to gefitinib or carboplatin-paclitaxel. In EGFR-mutant tumors, gefitinib improved PFS (HR 0.48); in EGFR-wild-type tumors, chemotherapy was superior (gefitinib HR 2.85) (Mok 2009, PMID 19692680).

IPASS lesson Consequence
Clinical enrichment produced a mixed molecular population Never-smoker/Asian/female phenotype is insufficient
Treatment effect reversed by mutation status EGFR is predictive, not merely prognostic
Crossover diluted OS separation PFS and treatment sequence require joint interpretation
Tissue availability constrained subgroup analysis Reflex testing became a system requirement

First-line metastatic therapy

Strategy Trial Efficacy signal Principal trade-off
Osimertinib FLAURA PFS 18.9 vs 10.2 mo, HR 0.46; OS 38.6 vs 31.8 mo, HR 0.80 (Soria 2018, PMID 29151359; Ramalingam 2020, PMID 31751012) Acquired resistance; chronic cardiac/QTc/ILD monitoring
Osimertinib + platinum-pemetrexed FLAURA2 Investigator-assessed PFS 25.5 vs 16.7 mo, HR 0.62 (Planchard 2023, PMID 37937763) More grade ≥3 adverse events and chemotherapy burden
Amivantamab + lazertinib MARIPOSA PFS 23.7 vs 16.6 mo vs osimertinib, HR 0.70 (Cho 2024, PMID 38924756) Infusion reactions, rash, paronychia, edema, VTE; IV burden

Osimertinib’s CNS penetration is clinically load-bearing because EGFR disease has high lifetime brain-metastasis risk. FLAURA reduced CNS progression versus first-generation comparators, but surveillance intervals and local treatment still depend on lesion burden and symptoms (Soria 2018, PMID 29151359).

Intensification should not be described as universally superior. FLAURA2 and MARIPOSA improved PFS in trial populations, but different control follow-up, toxicity, administration, crossover, mature OS, quality of life, and post-progression therapy determine net value (Planchard 2023, PMID 37937763; Cho 2024, PMID 38924756).

Adjuvant EGFR therapy

ADAURA randomized completely resected stage IB–IIIA classical EGFR-mutant NSCLC to osimertinib or placebo for three years after optional standard chemotherapy. The primary stage II–IIIA DFS HR was 0.17 in the initial report; the overall stage IB–IIIA DFS HR was 0.20 (Wu 2020, PMID 32955177). Mature analysis showed an overall-survival benefit, HR 0.49, with 5-year OS 88% versus 78% in stage IB–IIIA (Tsuboi 2023, PMID 37272535).

ADAURA question What is known What remains open
Does it delay recurrence? Large DFS effect including CNS recurrence reduction (Wu 2020, PMID 32955177) No
Does it improve OS? OS HR 0.49 in mature analysis (Tsuboi 2023, PMID 37272535) Magnitude under contemporary salvage
Is chemotherapy replaced? No; chemotherapy remained standard when indicated Optimal integration by stage and risk
Why three years? Trial-defined duration Whether shorter/longer or ctDNA-guided duration is better
Can relapse be retreated? Some tumors remain sensitive Prospective retreatment probability and sequencing

ALINA and perioperative immunotherapy make rapid preoperative genotyping equally important for non-EGFR drivers and for avoiding immune therapy in oncogene-driven tumors where benefit is uncertain.

Acquired resistance to earlier-generation TKIs

T790M increases ATP affinity and accounts for a large fraction of resistance after gefitinib/erlotinib/afatinib. AURA3 randomized T790M-positive progression to osimertinib versus platinum-pemetrexed: PFS 10.1 versus 4.4 months, HR 0.30, establishing re-biopsy-driven therapy (Mok 2017, PMID 27959700).

Mechanism after early TKI Detection Treatment implication
EGFR T790M Tissue or plasma; plasma-negative requires tissue Osimertinib
MET amplification Copy-number analysis, context-dependent threshold MET-directed combination trials/strategies
HER2 amplification / bypass Broad profiling Trial or pathway-directed strategy
Small-cell transformation Tissue morphology + RB1/TP53 context Small-cell chemotherapy framework
Histologic transformation Tissue Treatment follows transformed phenotype

Resistance after first-line osimertinib

Resistance is polyclonal and includes EGFR C797S, MET amplification, acquired fusions, RAS–MAPK reactivation, HER2 alterations, and small-cell/squamous transformation. C797S disrupts covalent osimertinib binding; whether it occurs in cis or trans with T790M determines theoretical sensitivity to combinations, but this is most relevant after sequential earlier-generation therapy (Roper 2020, PMID 32483558).

Pattern Why plasma helps Why tissue still matters
Multiple genomic clones Captures DNA shed across lesions Low shedding can miss mechanisms
MET amplification May be detected across sites Copy-number calling is purity-sensitive
C797S and compound mutations Reveals allelic mixtures Phasing may be incomplete
Transformation Often no unique plasma signature Requires morphology and immunophenotype

EGFR/TP53 co-mutant tumors with chromosomal instability and genome doubling are more likely to show mixed lesion-level TKI response, supporting combined radiographic and molecular assessment rather than a single RECIST summary (Hobor 2024, PMID 38871738).

Post-osimertinib strategy

Platinum-pemetrexed remains a backbone when no matched resistance mechanism exists. Amivantamab-based combinations target EGFR and MET and are moving earlier; the clinically important comparison includes efficacy, infusion burden, thromboembolism, skin/nail toxicity, and access (MARIPOSA programme, PMID 38942080).

Local ablative therapy can control a small number of progressing sites while continuing osimertinib when most disease remains suppressed, but this practice rests largely on selected observational data and oligoprogression biology rather than definitive EGFR-specific randomized survival evidence.

EGFR exon 20 insertion disease

Exon 20 insertions are structurally heterogeneous and usually insensitive to conventional-dose EGFR TKIs. PAPILLON randomized first-line amivantamab plus carboplatin-pemetrexed versus chemotherapy: median PFS 11.4 versus 6.7 months, HR 0.40 (Zhou 2023, PMID 37870976).

Exon 20 issue Clinical consequence
Variant diversity Assay must cover insertions beyond hotspot probes
Antibody therapy Infusion reaction, dermatologic toxicity, edema, VTE monitoring
CNS disease Antibody CNS penetration is limited; brain-specific strategy remains important
Older targeted agents Regulatory status and availability have changed; use current guideline version

Safety and sequencing

Toxicity Signal Control
Interstitial lung disease/pneumonitis Rare but potentially fatal across EGFR TKIs Hold for new respiratory symptoms; investigate urgently
QTc prolongation Osimertinib ECG/electrolytes in at-risk patients
Cardiomyopathy Osimertinib LVEF assessment when indicated
Rash/diarrhea/paronychia EGFR pathway class effect Proactive dermatologic/GI management
Infusion reaction Amivantamab, especially first infusion Split first dose/premedication/monitoring
VTE Amivantamab-lazertinib signal Risk awareness and protocol-based prophylaxis where recommended

Checkpoint inhibitor before EGFR TKI can complicate sequencing through pneumonitis/hepatitis risk. In a clinically stable patient, broad genotyping should return before PD-1/PD-L1 monotherapy is started.

Open questions

  • Which baseline features justify osimertinib intensification rather than monotherapy (FLAURA2, PMID 37937763; MARIPOSA, PMID 38924756)?
  • Can ctDNA clearance select adjuvant duration or safely identify patients who need no three-year therapy?
  • What fraction of adjuvant osimertinib benefit is cure versus delayed recurrence under modern retreatment (Tsuboi 2023, PMID 37272535)?
  • Which post-osimertinib resistance combinations improve OS in mechanism-defined cohorts?
  • How can CNS control be improved for exon 20 insertion disease (Zhou 2023, PMID 37870976)?

References

  1. Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009. PMID 19692680
  2. Soria JC, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018. PMID 29151359
  3. Ramalingam SS, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020. PMID 31751012
  4. Planchard D, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023. PMID 37937763
  5. Cho BC, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024. PMID 38924756
  6. Wu YL, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020. PMID 32955177
  7. Tsuboi M, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023. PMID 37272535
  8. Mok TS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017. PMID 27959700
  9. Zhou C, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023. PMID 37870976
  10. Shi Y, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014. PMID 24419411
  11. Roper N, et al. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Rep Med. 2020. PMID 32483558
  12. Hobor S, et al. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nat Commun. 2024. PMID 38871738
  13. Leighl NB, et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019. PMID 30988079
  14. Rolfo C, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021. PMID 34246791
  15. Lindeman NI, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018. PMID 29398453
  16. Tian W, et al. Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis. Future Oncol. 2022. PMID 35695676
  17. Cho BC, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2022. PMID 34911336
  18. Felip E, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann Oncol. 2024. PMID 38942080
  19. Brown H, et al. Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. J Thorac Oncol. 2020. PMID 31605792
  20. Papadimitrakopoulou VA, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020. PMID 32861806
  21. Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014. PMID 24893891
  22. Thress KS, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015. PMID 25939061
  23. Cancer Genome Atlas Research Network, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014. PMID 25079552
  24. Frankell AM, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023. PMID 37046096
  25. Howlader N, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020. PMID 32786189